ESC 2024: Elixir’s stent contender hits primary endpoint in CAD trial

-




lixir Medical’s DynamX Bioadaptor scaffold for coronary artery disease (CAD) has produced positive results in a randomised controlled trial comparing the implant to a drug-eluting stent.

Presenting the data at a Hot-Line session on the final day of the 2024 European Society of Cardiology Congress held in London, UK, from 30 August to 2 September, Elixir said trial (NCT04562805) – named INFINITY-SWEDEHEART – met its primary endpoint of target lesion failure (TLF) non-inferiority.

The study’s principal investigator David Erlinge said at the Hot-Line session: “The results confirm the novel impact of the Bioadaptor in coronary artery disease treatment through its unique mechanism of action of restoring the haemodynamic modulation of a diseased artery.”


The patients enrolled in the study were those with chronic coronary syndrome or acute coronary syndrome and were indicated for a percutaneous intervention with stent implantation. A total of 2,400 patients across sites in Sweden were involved in the registry-based clinical trial.

Elixir was comparing its implant against Medtronic’s Resolute Onyx zotarolimus, a stent that releases the immunosuppressant drug zotarolimus. After 12 months, the DynamX bioadaptor, which instead releases sirolimus – also an immunosuppressant – had a TLF of 2.35% versus 2.77% for the marketed stent.

Comments

Post a Comment

Popular posts from this blog

Cell therapy weekly: partnerships for advancing cell and gene therapies

-
Image
This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...
Read more

DBT, CSCR develop 1st human gene therapy for Haemophilia A in India

-
Image
Offering hope to around 136,000 Haemophilia A patients in India, the Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore, announced that they have successfully executed a first-in-human gene therapy using lentiviral vectors for the disease. Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal and external bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia. Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, intravenous (IV) access in children, and low patient acceptance.The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results, according to scientists involved in the research. “The therapy successfully produced zero annualised bleeding rates in all five enrolled participan...
Read more